These negative results based on solid evidence will help surgeons to avoid raising false hopes and circumvent the use of futile therapies.
Expert Commentary: Cannabis Shows No Meaningful Benefit for Brachial Plexus Injury Pain, But the Question Isn’t Closed
Its negative results should not close the door to future studies of other conditions that may respond to cannabinoids.
Cannabis for Pain Management: A Smarter Way to Think About Relief
Pain is not one thing, and cannabis is not one thing either. This guide explains how to think more clearly about cannabis for pain management by matching product type, cannabinoid balance, timing, and dose strategy to the kind of pain you are actually having.
ARTELO BIOSCIENCES, INC. SEC 10-K Report – TradingView
WHY IT MATTERS: If endocannabinoid-targeted pharmaceuticals like these gain FDA approval, patients dealing with cancer-related weight loss and chemotherapy nerve pain could eventually have insurance-covered, standardized treatment options that work through the same system cannabis does. CLINICAL OVERVIEW: Artelo Biosciences is advancing pharmaceutical candidates that target the endocannabinoid system, including ART27.13 for cancer-related anorexia and ART26.12 for chemotherapy-induced peripheral neuropathy. These drug development programs represent a growing trend of biotech companies working to create FDA-approvable medications that modulate endocannabinoid pathways rather than relying solely on plant-derived cannabinoids.